Liver Function Biomarker in Patients on Anticoagulant Therapy at Usmanu Danfodiyo Unversity Teaching Hospital, Sokoto, Nigeria

Oduola Taofeeq^1, , Bature Farida¹, Ndakotsu Mohammed Alhaji², Yakubu Abdulmumini³, Dallatu Mohammed Kabiru¹ and Mainasara Abdullahi Suleiman⁴

¹Faculty of Medical Laboratory Sciences, Department of Chemical Pathology, Usmanu Danfodiyo University, Sokoto, Nigeria

²Department of Haematology and Blood Transfusion, College of Health Sciences, Usmanu Danfodio University, Sokoto, Nigeria

³Department of Medicine, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria

⁴Department of Chemical Pathology, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria

Cite this paper

Oduola Taofeeq, Bature Farida, Ndakotsu Mohammed Alhaji, Yakubu Abdulmumini, Dallatu Mohammed Kabiru and Mainasara Abdullahi Suleiman. Liver Function Biomarker in Patients on Anticoagulant Therapy at Usmanu Danfodiyo Unversity Teaching Hospital, Sokoto, Nigeria. American Journal of Clinical Medicine Research. 2015; 3(3):37-41. doi: 10.12691/AJCMR-3-3-1

Abstract

Background: Drug induced hepatotoxicity have been known to be a common cause of liver failure. Drugs can either have a short-term or long-term adverse effect. The risk of side effect varies from drug to drug and from patient to patient. Most of the patients that need anticoagulant therapy are on the drugs for a long period, hence liver function may be impaired during the course of therapy this study was designed to investigate the effect of anticoagulant drugs on liver function. Methods: Thirty patients who have been on anticoagulant therapy between 1to 20 years (X5.8years), 30 patients that were yet to commence anticoagulant therapy but with the same clinical condition and 30 apparently healthy subjects were recruited for the study. Effect of duration of therapy on liver function were also assessed. Patients with background liver disease from any cause were excluded from the study. Five ml of blood were collected from each of the participant and liver function biomarkers estimated using standard techniques. Result: Therewere statistically significant increases (P<0.001) in values of aspartate transaminase (AST), alanine transaminase (ALT), and gammaglutamyl transferase(GGT) in patients on anticoagulant therapy and patients that were not on anticoagulant therapy when compared with control subjects but the increases were within the reference range. There was no significant difference (P>0.001) in alkaline phosphatase (ALP), total protein (TP), albumin (ALB), total bilirubin (TB) and direct bilirubin (DB) values between the patients and the control group. Conclusion: The slight elevation in liver function biomarkers assessed in patients on anticoagulant therapy could not be linked to the effect of the drug because patients with the same clinical conditions that were not on anticoagulant therapy showed the same elevation of the biomarkers. We did not observe effect of duration of therapy on liver function. The liver function biomarkers assessed were within the reference range in both the patients on therapy and those not on therapy. From our findings, we did not observe hepatotoxicity among our subjects.

Keywords

liver function, biomarkers, anticoagulant therapy, patients, adverse effect

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Weinshilboum, R, Inheritance and drug response. N Engl J Med, 348:529-37, 2003.
[2]	Guengerich, F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol, 14:611-50, 2001.
[3]	Lee, W.M. Drug Induced Hepatotoxicity.N Eng J Med, 349: 474-485, 2003.
[4]	Bishop,M.L, Fody,E.B, Schoeff, L.E. The liver function In: Clinical chemistry, Techniques, Principle and Correlations, Lippincott Williams & Wilkins, Philadelphia, USA, 6thed.516-529, 2010.
[5]	Parveen, K., Clark, M. Gastrointestinal diseases:In:Clinical Medicine, 6thed. P: 318-384, 2006.
[6]	Remmer, H. The role of liver in drug metabolism. American J of Medicine. 49: 617-629, 1970.
[7]	Rang, H., P., Dale, M., M., Ritter, J., M., Flower, R., J. Homeostasis and Thrombosis. In: Pharmacology 6thed. 331-344, 2007.
[8]	Hirsh, J,Dalen, J.E, Deykin, D, Poller L, Bussey H. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 108(4 Suppl):231S-46S, 1995.
[9]	Stein, P.D,, Alpert, J.S., Copeland, J., Dalen J.E., Goldman, S., Turpie, A.G. Antithrombotic therapy in patients with mechanical and biologic prosthetic heart valves. Chest, 108(4 Suppl):371S-9S[Published erratum in Chest 1996;109:592], 1995.
[10]	Levine, H.J, Pauker S.G, Eckman M.H. Antithrombotic therapy in valvular heart disease. Chest, 108(4 Suppl):360S-70S, 1995.
[11]	Schulman, S., Granqvist S., Holmstrom M., Carlsson A., Lindmarker P., Nicol P, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med, 336: 393-8, 1997.
[12]	Laupacis, A., Albers G., Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest, 108(4 Suppl): 352S-9S, 1995.
[13]	Levine M.N, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost, 74: 606-11, 1995.
[14]	Reitman S.S., Frankel S. A coulorimetric method for the determination serum transaminase activity. Amer. J. Clin. Path., 28: 56-68, 1957.
[15]	Recommendation of German Society of Clinical Chemistry (Rec. Gscc). Optimised standard colorimetric methods. Journal of Clinical Chemistry and Clinical Biochemistry 10: 182, 1972.
[16]	Tietz N.W. Clinical Guide on Laboratory Tests. 3rd ed. Philadelphia Pa WB Saunders Company, 286, 1995.
[17]	Henry F.R, Canon D.C, Winkelman J.W. Clinical Chemistry, Principles and Techniques, 2nd ed. Harper and Row Publishers, New York, 1974.
[18]	18. Höhler T, Schnütgen M, Helmreich-Becker I, Mayet W.J, Mayer Z.U.M, Büschenfelde K.H.Drug-induced hepatitis: a rare complication of oral anticoagulants. J Hepatol. Sep; 21(3): 447-9, 1994.
[19]	Ehrenforth S, Schenk J.F, Scharrer I.Liver damage induced by coumarin anticoagulants. Semin Thromb Hemost. 25(1): 79-83, 1999.
[20]	Nipun A., Samuel, Z. G.Anticoagulants and transaminases elevation. Circulation; 113:e698-e702, 2006.
[21]	Bamanikar A, Hiremath S. Hepatotoxic reaction to warfarin in a recovering hepatitis patient with hypoalbuminemia. J Assoc Physicians India, 50: 1456, 2002.
[22]	Chaudhry S, Oelsner D. Cholestatic reaction to warfarin. Am J Gastroenterol. 90: 853, 1995.
[23]	Bux-Gewehr I, Zotz R.B, Scharf R.E. Phenprocoumon-induced hepatitis in a patient with a combined hereditary hemostatic disorder. Thromb Haemost. 83: 799–800, 2000.
[24]	Hinrichsen H, Luttges J, Kloppel G, Folsch UR, Schmidt WE. Idiosyncratic drug allergic phenprocoumon-induced hepatitis with subacute liver failure initially misdiagnosed as autoimmune hepatitis. Scand J Gastroenterol. 36: 780–783, 2001.
[25]	Schimanski C.C, Burg J, Mohler M, Hohler T, Kanzler S, Otto G, Galle P.R, Lohse A.W. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. J Hepatol,41: 67-74, 2004.
[26]	Adler E, Benjamin SB, Zimmerman HJ.Cholestatic hepatic injury related to warfarin exposure. Arch Intern Med.146(9):1837-9, 1986.